Previous 10 | Next 10 |
2023-04-12 06:00:00 ET Summary If a stock has a high short interest, it means that there are many investors who have bet against the stock and shorted it. The collapse of Silicon Valley Bank and the ensuing domino effect has resulted in short sellers wanting to capitalize on wides...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately. “I am honored to succeed Bob Ingram. He was a model of eff...
RESEARCH TRIANGLE PARK, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today acknowledged the many contributions of Robert A. Ingram, the company’s chairman of the board, who recently passed away. We are very saddened by his loss and our th...
2023-03-16 17:50:07 ET Summary BioCryst Pharmaceuticals is a biotech company that focuses on developing treatments for rare diseases. Its main product, Orladeyo, is an oral medication approved by the FDA to treat hereditary angioedema. BioCryst's full-year 2022 revenue for Orladey...
2023-03-08 15:23:13 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) announced Wednesday that an expert panel in Canada recommended its hereditary angioedema (HAE) therapy Orladeyo (berotralstat) for reimbursement. According to the company, the Canadian Drug Expert Committee (...
INTENDED FOR CANADIAN AUDIENCES ONLY RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issu...
2023-03-08 14:01:31 ET Summary BioCryst Pharmaceuticals, Inc. has one blockbuster potential marketed drug, but not much of a pipeline. Last year, they shelved two separate programs for different reasons. BioCryst Pharmaceuticals is cash rich and makes an ideal buyout candidate...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event. For further details see: BioCryst Pharmaceuticals (BCRX) Presents At J.P. MORGAN HEALTHCARE CONFERENCE
— Final safety and effectiveness analysis from APeX-S showed ORLADEYO 150 mg resulted in a median attack rate of 0.0 attacks per month in 20 of 24 months — RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024. BioCryst management will host a conference call and webcast ...
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...